Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 25, 2018

Primary Completion Date

July 31, 2022

Study Completion Date

August 31, 2022

Conditions
Nicotine AddictionDrug AddictionDrug DependenceSubstance Use DisorderTobacco Dependence
Interventions
DEVICE

Treatment A with device Clickotine® (Active intervention)

The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.

DEVICE

Treatment B with smoking education (control)

The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.

Trial Locations (1)

10013

Click Therapeutics, New York

Sponsors
All Listed Sponsors
lead

Click Therapeutics, Inc.

INDUSTRY

NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification | Biotech Hunter | Biotech Hunter